You can find individual care pathways for patients with a class A and class B CPS and for individuals with a class C CPS. Furthermore, the authors provide an algorithmic approach to these agents in the transplant populace, focusing on first line use of glucagon-like peptide one (GLP-one) agonists https://gloriaa577qni5.wikicorrespondence.com/user